TY - JOUR
T1 - Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection
AU - Abdul Basit, Syed
AU - Dawood, Altaf
AU - Ryan, John
AU - Gish, Robert
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/7/3
Y1 - 2017/7/3
KW - Chronic hepatitis B
KW - adverse effects
KW - bone mineral density
KW - creatinine
KW - tenofovir alafenamide
KW - tenofovir disoproxil fumarate
KW - Alanine
KW - Hepatitis B e Antigens/metabolism
KW - Humans
KW - Creatinine/blood
KW - Hepatitis B, Chronic/drug therapy
KW - Tenofovir/adverse effects
KW - Animals
KW - Time Factors
KW - Antiviral Agents/adverse effects
KW - Bone Density/drug effects
KW - Adenine/adverse effects
KW - DNA, Viral/drug effects
UR - https://www.scopus.com/pages/publications/85019720558
UR - https://www.scopus.com/pages/publications/85019720558#tab=citedBy
UR - https://www.mendeley.com/catalogue/71afecd1-759b-3a31-a7e7-082688480b32/
U2 - 10.1080/17512433.2017.1323633
DO - 10.1080/17512433.2017.1323633
M3 - Article
C2 - 28460547
AN - SCOPUS:85019720558
SN - 1751-2433
VL - 10
SP - 707
EP - 716
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
IS - 7
ER -